Nereen A. Almosilhy

Nereen A. Almosilhy

Auto-generated profile, based on publicly available information

Nereen A. Almosilhy

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta, Egypt

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2025 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
HMHamdy A. Makhlouf
Hamdy A. Makhlouf
AHAmr Hassan
Amr Hassan
NANereen A. Almosilhy
Nereen A. Almosilhy
AOAhmed S.A. Osman
Ahmed S.A. Osman
SRShrouk Ramadan
Shrouk Ramadan
MAMoaz Elsayed Abouelmagd
Moaz Elsayed Abouelmagd
Background: Statins or 3‑hydroxy‑3‑methyl‑glutarylcoenzyme A (HMG‑CoA) reductase inhibitors are medications that act by reducing the cholesterol content of liver cells Moreover, statins have been found to improve endothelial function and reduce vascular wall inflammation. A growing body of research suggests that statins are associated with less risk of migraine, and they can be used to treat symptoms. However, the evidence has been inconclusive, so we aim to investigate the nature and strength of the effect of statins on the prevention and prophylaxis of migraines. Methods: We conducted a comprehensive systematic search across multiple electronic databases, including PubMed, Scopus, Web of Science, and the Cochrane Library, from inception until October 2024, to include studies on the association between statins use and migraine. The outcomes of interest involved the association of the HMG-CoA reductase gene with the risk of migraine, as well as the association and efficacy of statins in migraine patients. Results: Thirteen studies were included in our systematic review. Mendelian Randomization (MR) studies revealed that expression of HMGCR was associated with an increased risk of migraine with odds ratio (OR) ranging from 1.38 to 1.55 (P < 0.001). Three observational studies investigating the relationship between statins and migraine risk demonstrated a protective effect, with odds ratios ranging from 0.73 to 0.94 (P < 0.001). The findings suggest a significant reduction in overall migraine risk, particularly for migraines with aura and in patients with higher vitamin D levels. Meta-analysis of randomized controlled trials (RCTs) showed that statins significantly reduced monthly migraine frequency (MD= -3.16, 95%CI= [-5.79, -0.53]; p = 0.02, I2 = 79%; P = 0.03). RCTs supported the efficacy of statins in reducing migraine frequency, days, and intensity compared to placebo. Conclusions: Statins, already well-established for cardiovascular benefits, emerge as a promising dual-purpose therapy for many neurological disorders. The association between the HMGCR gene and increased migraine risk, coupled with the possible efficacy of statins in reducing migraine frequency, may open new avenues for migraine prophylaxis. However, the variability in study design hinders definitive conclusions, so larger studies with longer follow-ups are required to ascertain both findings.

5 June 2025 in Neurosurgical Review
Verified
Journal Article
Open access
PDF file
AEAmr Elrosasy
Amr Elrosasy
MHMahmoud Diaa Hindawi
Mahmoud Diaa Hindawi
QNQasi Najah
Qasi Najah
MZMohamed Abo Zeid
Mohamed Abo Zeid
HEHatem Eldeeb
Hatem Eldeeb
RMRashad G. Mohamad
Rashad G. Mohamad
Carpal Tunnel Syndrome (CTS) is a common peripheral nerve entrapment disorder with a high global burden. Various surgical techniques have been developed to optimize symptom relief and minimize postoperative morbidity. This network meta-analysis (NMA) aimed to compare the relative efficacy and safety of different carpal tunnel release (CTR) procedures. We conducted a systematic review and NMA of randomized controlled trials (RCTs) comparing surgical CTR techniques. Outcomes included symptom severity, pain scores, functional status, patient-reported outcomes, operative time, and adverse events. Data were synthesized using the frequentist approach with the netmeta package in R. Confidence in network estimates was evaluated using the CINeMA framework. Thirty-two RCTs comprising 2,916 patients were included. One-port and two-port endoscopic CTR (ECTR) techniques demonstrated superior symptom relief compared to conventional open CTR (COCTR), particularly at three months (two-port ECTR: SMD = –4.47; 95% CI: –5.67 to –3.26). One-port ECTR consistently showed better functional outcomes across all timepoints, including improved grip (SMD = 1.37; 95% CI: 0.35 to 2.39) and pinch strength. Pain was significantly reduced with two-port ECTR at one and three months. Ultrasound-guided CTR (CTR-US) showed the highest patient satisfaction (OR = 6.89; 95% CI: 1.87 to 25.43) and a significantly shorter return-to-work duration. The double tunnels technique (DTT) had the lowest risk of adverse events (OR = 0.05; 95% CI: 0.01 to 0.42). Operational time and scar tenderness were comparable across all techniques. Heterogeneity was generally low to moderate across outcomes, and CINeMA assessments indicated moderate to low confidence in several comparisons. Endoscopic techniques, particularly one- and two-port ECTR, offer superior outcomes in symptom severity and functional recovery compared to COCTR. CTR-US appears to maximize patient satisfaction and early return to work, while DTT is associated with the fewest complications. These findings can guide individualized, evidence-based treatment decisions in CTS surgery.

4 November 2025 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
MAMoaz Elsayed Abouelmagd
Moaz Elsayed Abouelmagd
NANereen A. Almosilhy
Nereen A. Almosilhy
HMHamdy A. Makhlouf
Hamdy A. Makhlouf
AHAmr Hassan
Amr Hassan
AOAhmed S. A. Osman
Ahmed S. A. Osman
Ahmed NegidaAhmed Negida
Ahmed Negida
Background: Dementia is a growing public health concern, affecting over 55 million people worldwide, with Alzheimer’s disease (AD) being the most prevalent cause. Cholinesterase inhibitors (ChEIs) and memantine remain the mainstay pharmacological treatment for AD and other dementias, despite their modest benefits and potential adverse effects. The safety profiles of these medications, particularly at different doses and formulations, remain inadequately explored, necessitating a comprehensive evaluation. Methods: This systematic review and network meta-analysis (NMA) will assess the safety of ChEIs (donepezil, galantamine, rivastigmine) and memantine in dementia treatment. We will include randomized controlled trials (RCTs) with ≥ 3 months of follow-up, evaluating adverse events (AEs), serious adverse events (SAEs), and treatment discontinuation rates. A comprehensive literature search will be conducted in PubMed, Scopus, Web of Science, and Cochrane Library, with additional searches in Google Scholar and reference lists of included studies. Data extraction will follow a standardized approach, and study quality will be assessed using the Cochrane risk-of-bias tool-2. A Frequentist or Bayesian NMA framework will be used to compare safety profiles, with heterogeneity assessed using the I 2 test. Discussion: By addressing gaps in prior NMAs, this study aims to provide an in-depth evaluation of safety outcomes associated with different ChEI and memantine doses and formulations across various dementia types. The findings will support clinicians in making informed treatment decisions and guide future research and policy development for dementia management. Systematic review registration: PROSPERO (CRD42025642902).

27 February 2026 in BMC Cancer
Verified
Journal Article
Open access
PDF file
QNQasi Najah
Qasi Najah
HMHamdy A. Makhlouf
Hamdy A. Makhlouf
AOAhmed S. A. Osman
Ahmed S. A. Osman
NANereen A. Almosilhy
Nereen A. Almosilhy
MAMariam A.I. Abusalah
Mariam A.I. Abusalah
HAHussien Ahmed H. Abdelgawad
Hussien Ahmed H. Abdelgawad
The treatment landscape for extensive-stage small-cell lung cancer (ES-SCLC) has advanced with the introduction of immunotherapy, targeted therapy, and nov

12 February 2026 in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Verified
Journal Article
Closed access
MHMohamed Mohsen Helal
Mohamed Mohsen Helal
NANereen A. Almosilhy
Nereen A. Almosilhy
DADina Essam Abo-Elnour
Dina Essam Abo-Elnour
RJRana Suhail Younis Jaffal
Rana Suhail Younis Jaffal
EAEman Gomaa Allam
Eman Gomaa Allam
MMMostafa Meshref
Mostafa Meshref
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive motor neuron loss and profound systemic metabolic dysfunction, including hypermetabolism, weight loss, insulin resistance, and altered glucose and lipid homeostasis. Increasing recognition of these metabolic abnormalities has driven interest in repurposing antidiabetic therapies, particularly glucagon-like peptide-1 (GLP-1) and GLP-1 receptor agonists (GLP-1RAs), for ALS. Beyond their established metabolic actions, GLP-1RAs exert pleiotropic effects relevant to neurodegeneration, including modulation of neuroinflammation, mitochondrial function, oxidative stress, excitotoxicity, and cell-survival signaling, with selected agents demonstrating central nervous system penetration. This narrative review summarizes current knowledge on metabolic impairment in ALS and critically evaluates the mechanistic rationale, preclinical evidence, and emerging clinical data supporting or opposing the use of GLP-1-based therapies in this disease. Preclinical studies suggest that GLP-1 signaling can provide neuroprotective and neurotrophic effects in ALS models, although findings are heterogeneous and highly dependent on compound selection, delivery strategy, and experimental design. In contrast, available clinical evidence is limited and does not demonstrate therapeutic benefit in ALS, while raising important safety concerns, particularly related to weight loss, lean mass reduction, and altered glucose regulation, factors associated with a worse prognosis in ALS. Collectively, current data indicate that although GLP-1-based therapies may have compelling biological plausibility and beneficial effects in other neurodegenerative disorders (NDGs), their role in ALS remains uncertain and potentially harmful. Well-designed, ALS-specific clinical studies are required to clarify safety, efficacy, and patient selection before GLP-1RAs can be considered for therapeutic use in this vulnerable population.

18 September 2026 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
OBOmer Hussein Alwi Bin-Sahel
Omer Hussein Alwi Bin-Sahel
PNPriyanshi Nada
Priyanshi Nada
ASAtiqullah Sadaqat
Atiqullah Sadaqat
AGAbdallah Al Ghnaimat
Abdallah Al Ghnaimat
MMMohammad Mahadin
Mohammad Mahadin
PPParag N. Patel
Parag N. Patel
Severe acute pancreatitis (SAP) is the most critical form of acute pancreatitis (AP), characterized by a dysregulated systemic inflammatory response that d